These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 19165225)

  • 41. Functions of p53 in metabolism and invasion.
    Vousden KH
    Biochem Soc Trans; 2009 Jun; 37(Pt 3):511-7. PubMed ID: 19442244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Friend or Foe: MicroRNAs in the p53 network.
    Luo Z; Cui R; Tili E; Croce C
    Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.
    Timmerman DM; Remmers TL; Hillenius S; Looijenga LHJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065345
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of
    Wujcicka W; Zając A; Stachowiak G
    In Vivo; 2019; 33(3):917-924. PubMed ID: 31028217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MDM2-p53 pathway in hepatocellular carcinoma.
    Meng X; Franklin DA; Dong J; Zhang Y
    Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
    Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
    Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.
    Peller S
    Semin Cancer Biol; 1998; 8(5):379-87. PubMed ID: 10101803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.
    Samuel N; Id Said B; Guha T; Novokmet A; Li W; Silwal-Pandit L; Børrsen-Dale AL; Langerød A; Hudson TJ; Malkin D
    Hum Mutat; 2017 Mar; 38(3):265-268. PubMed ID: 27957778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different mutation profiles associated to P53 accumulation in colorectal cancer.
    López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
    Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorphisms in the p53 pathway.
    Pietsch EC; Humbey O; Murphy ME
    Oncogene; 2006 Mar; 25(11):1602-11. PubMed ID: 16550160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
    Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
    [No Abstract]   [Full Text] [Related]  

  • 56. A novel germline TP53 mutation p.Pro190Arg detected in a patient with lung and bilateral breast cancers.
    Krześniak M; Butkiewicz D; Rachtan J; Matuszczyk I; Grzybowska E; Rusin M
    Adv Med Sci; 2017 Sep; 62(2):207-210. PubMed ID: 28499267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive characterization of genes associated with the TP53 signal transduction pathway in various tumors.
    Ohnami S; Ohshima K; Nagashima T; Urakami K; Shimoda Y; Saito J; Naruoka A; Hatakeyama K; Mochizuki T; Serizawa M; Ohnami S; Kusuhara M; Yamaguchi K
    Mol Cell Biochem; 2017 Jul; 431(1-2):75-85. PubMed ID: 28258440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.
    Van Maerken T; Rihani A; Van Goethem A; De Paepe A; Speleman F; Vandesompele J
    Cancer Lett; 2014 Mar; 344(2):157-65. PubMed ID: 24262662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disrupting TP53 in mouse models of human cancers.
    Parant JM; Lozano G
    Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.